GlassScriptPhysician profile
Dana Berg
NPI 1013283514
$1,220.47
in general payments reported to CMS, 2019-2025
18 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2021: $78.17 · 2022: $298 · 2023: $84.10 · 2024: $319 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $265.10 | 2021-2024 | Entyvio, Eohilia |
| Abbvie INC. | $211.16 | 2019-2025 | Rinvoq, Skyrizi |
| Celgene Corporation | $180.90 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $113.34 | 2019 | |
| Janssen Biotech, INC. | $58.15 | 2022-2025 | Simponi, Simponi Aria, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.06 | 2024 | Xifaxan |
| Novo Nordisk INC | $45.13 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $40.88 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $38.88 | 2025 | Givlaari |
| Madrigal Pharmaceuticals | $37.03 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $33.20 | 2025 | Overstitch Endoscopic Suturing System |
| Lilly USA, LLC | $31.57 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $22.47 | 2024 | |
| Pfizer INC. | $22.33 | 2024 | |
| Ardelyx, INC. | $20.91 | 2025 | Ibsrela |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $20.22 | 2024 | Zymfentra |
| Fujifilm Healthcare Americas Corporation | $16.60 | 2025 | |
| Ferring Pharmaceuticals INC. | $13.54 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.